ArticleJournal of managed care & specialty pharmacy2026
Risk of herpes zoster among adults in the United States initiating immunosuppressive therapy: A retrospective cohort study.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients immunosuppressed because of disease and/or therapy are at increased risk of developing herpes zoster (HZ) and related complications. However, HZ risk due to immunosuppressive medication remains underexplored across a broad spectrum of medication classes and conditions.
objectiveTo estimate HZ risk among US adults initiating immunosuppressive therapy, across underlying conditions.
methodsThis retrospective study used administrative claims from the Optum Research Database (October 1, 2015, to December 31, 2022) to identify incident HZ diagnoses and the proportion of HZ with complications. Included patients were aged 18 years or older and had at least a 12-month baseline period of continuous enrollment with medical and pharmacy benefits. Analyses produced incidence rates (IRs) of HZ during periods of immunosuppression and nonimmunosuppression and compared patients initiating immunosuppressive therapy (immunosuppressed subcohort) vs matched controls who did not (nonimmunosuppressed subcohort). Cox regression analyses compared HZ hazards and a logistic regression model compared the difference in the occurrence of postherpetic neuralgia (PHN) following HZ diagnosis.
resultsIn patients initiating immunosuppressive medications (N = 528,283), the overall HZ IR was 18.2 (95% CI = 17.9-18.4) per 1,000 person-years. Patients with the highest IRs were those treated with Janus kinase inhibitors (30.5 [95% CI = 25.0-36.9] per 1,000 person-years), rituximab (27.8 [95% CI = 25.2-30.6] per 1,000 person-years), or cyclophosphamide (27.5 [95% CI = 19.3-38.1] per 1,000 person-years). Patients had a higher HZ risk when using immunosuppressive medications (adjusted hazard ratio 2.86 [95% CI = 2.76-2.95]) and with increasing numbers of immunosuppressive medication classes (one vs none: 2.45 [95% CI = 2.37-2.54]; at least 2 vs none: 4.04 [95% CI = 3.87-4.21]). The immunosuppressed subcohort had a higher HZ hazard (adjusted hazard ratio: 1.39 [95% CI = 1.35-1.43]), higher frequency of HZ complications (21.4% vs 18.8% of HZ cases developed PHN,
conclusionsImmunosuppressive medication use was associated with a higher risk of HZ and HZ-related complications. Measures to prevent HZ before immunosuppressive treatment initiation should be considered according to Advisory Committee on Immunization Practices recommendations and other professional organizations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.